Terms: = Breast cancer AND MYC, c-Myc, 4609, ENSG00000136997
2709 results:
1. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.
Lee M; Yoo TK; Chae BJ; Lee A; Cha YJ; Lee J; Ahn SG; Kang J
Sci Rep; 2024 May; 14(1):11278. PubMed ID: 38760384
[TBL] [Abstract] [Full Text] [Related]
2. Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA.
Chen M; Zhu H; Li J; Luo D; Zhang J; Liu W; Wang J
Ann Med; 2024 Dec; 56(1):2282184. PubMed ID: 38738386
[TBL] [Abstract] [Full Text] [Related]
3.
Di-Iacovo N; Ferracchiato S; Pieroni S; Scopetti D; Castelli M; Piobbico D; Pierucci L; Gargaro M; Chiasserini D; Servillo G; Della-Fazia MA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731819
[No Abstract] [Full Text] [Related]
4. Effects of CD44 siRNA on inhibition, survival, and apoptosis of breast cancer cell lines (MDA-MB-231 and 4T1).
Dehbokri SG; Noorolyai S; Baghbani E; Moghaddamneshat N; Javaheri T; Baradaran B
Mol Biol Rep; 2024 May; 51(1):646. PubMed ID: 38727931
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma.
Chang HY; Dermawan JK; Kuba MG; Crago AM; Singer S; Tap W; Chi P; D'Angelo S; Rosenbaum E; Antonescu CR
Genes Chromosomes Cancer; 2024 May; 63(5):e23240. PubMed ID: 38722225
[TBL] [Abstract] [Full Text] [Related]
6. Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling.
Chi LH; Redfern AD; Roslan S; Street IP; Burrows AD; Anderson RL
Cell Commun Signal; 2024 Apr; 22(1):248. PubMed ID: 38689334
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA DLG5-AS1 facilitates breast cancer cell proliferation and invasion by promoting EZH2-mediated transcriptional silencing of SFRP1.
Cai Y; Liu Y; Sun Y; Ren Y
Arch Biochem Biophys; 2024 Jun; 756():110018. PubMed ID: 38677505
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
9. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
Perri G; Vilas Boas VG; Nogueira MRS; Mello Júnior EJF; Coelho AL; Posadas EM; Hogaboam C; Cavassani KA; Campanelli AP
Cancer Immunol Immunother; 2024 Apr; 73(6):110. PubMed ID: 38662248
[TBL] [Abstract] [Full Text] [Related]
10. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models.
Rypens C; Van Berckelaer C; Berditchevski F; van Dam P; Van Laere S
Int Rev Cell Mol Biol; 2024; 384():77-112. PubMed ID: 38637101
[TBL] [Abstract] [Full Text] [Related]
11. The myc-associated zinc finger protein epigenetically controls expression of interferon-γ-stimulated genes by recruiting STAT1 to chromatin.
Xiao T; Li X; Felsenfeld G
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2320938121. PubMed ID: 38635637
[TBL] [Abstract] [Full Text] [Related]
12. Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative breast cancer.
Fan T; Huang Y; Liu Z; Huang J; Ke B; Rong Y; Qiu H; Zhang B
Drug Des Devel Ther; 2024; 18():1115-1131. PubMed ID: 38618280
[TBL] [Abstract] [Full Text] [Related]
13. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract] [Full Text] [Related]
14. U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-myc expression.
Zhang W; Song X; Jin Z; Zhang Y; Li S; Jin F; Zheng A
Breast Cancer Res; 2024 Apr; 26(1):60. PubMed ID: 38594783
[TBL] [Abstract] [Full Text] [Related]
15. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
Lin CJ; Jin X; Ma D; Chen C; Ou-Yang Y; Pei YC; Zhou CZ; Qu FL; Wang YJ; Liu CL; Fan L; Hu X; Shao ZM; Jiang YZ
Cancer Cell; 2024 Apr; 42(4):701-719.e12. PubMed ID: 38593782
[TBL] [Abstract] [Full Text] [Related]
16. Development, synthesis and validation of improved c-myc/Max inhibitors.
Yıldırım S; Kocabaş F; Mermer A
J Cell Mol Med; 2024 Apr; 28(8):e18272. PubMed ID: 38568057
[TBL] [Abstract] [Full Text] [Related]
17. Bone Endosteal Mimics Regulates breast cancer Development and Phenotype.
Ben Ghedalia Peled N; Hoffman DK; Barsky L; Zer NS; Amar K; Rapaport H; Gheber LA; Zhang XH; Vago R
Biomacromolecules; 2024 Apr; 25(4):2338-2347. PubMed ID: 38499995
[TBL] [Abstract] [Full Text] [Related]
18. Characterization of MYBL1 Gene in Triple-Negative breast cancers and the Genes' Relationship to Alterations Identified at the Chromosome 8q Loci.
Player A; Cunningham S; Philio D; Roy R; Haynes C; Dixon C; Thirston L; Ibikunle F; Boswell TA; Alnakhalah A; Contreras J; Bell M; McGuffery T; Bryant S; Nganya C; Kanu S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473786
[TBL] [Abstract] [Full Text] [Related]
19. RB1 loss induces quiescent state through downregulation of RAS signaling in mammary epithelial cells.
Gong L; Voon DC; Nakayama J; Takahashi C; Kohno S
Cancer Sci; 2024 May; 115(5):1576-1586. PubMed ID: 38468443
[TBL] [Abstract] [Full Text] [Related]
20. MicroRNA-561-3p indirectly regulates the PD-L1 expression by targeting ZEB1, HIF1A, and myc genes in breast cancer.
Yousefi A; Sotoodehnejadnematalahi F; Nafissi N; Zeinali S; Azizi M
Sci Rep; 2024 Mar; 14(1):5845. PubMed ID: 38462658
[TBL] [Abstract] [Full Text] [Related]
[Next]
